Comprehensive analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in melanoma. Stylianakis D, Stylianakis I, Benjamin HA, et al. Comprehensive analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in melanoma. Critical reviews in oncology/hematology. 2025;215:104962. doi:10.1016/j.critrevonc.2025.104962 Read more